Journal of Cellular Biochemistry · 2013 · 62 citations · 22 references
MedicineMolecular BiologyPharmacologyBone MetabolismGene ExpressionInflammationBone DevelopmentBone FormationBone TissueOsteoblast BiologyOsteogenesisOsteoporosisGlucocorticoid Effects On BoneGlucocorticoid Effects On OsteoblastsGlucocorticoid-induced Osteoporosis TreatmentInduced Pluripotent Stem CellsRunx2 SignalingRunx2 Transcription FactorRunx2 Transcriptional RegulationRunx2-mediated Regulation
The efficacy of glucocorticoids (GCs) in treating a wide range of autoimmune and inflammatory conditions is blemished by severe side effects, including osteoporosis. The chief mechanism leading to GC-induced osteoporosis is inhibition of bone formation, but the role of RUNX2, a master regulator of osteoblast differentiation and bone formation, has not been well studied. We assessed effects of the synthetic GC dexamethasone (dex) on transcription of RUNX2-stimulated genes during the differentiation of mesenchymal pluripotent cells into osteoblasts. Dex inhibited a RUNX2 reporter gene and attenuated locus-dependently RUNX2-driven expression of several endogenous target genes. The anti-RUNX2 activity of dex was not attributable to decreased RUNX2 expression, but rather to physical interaction between RUNX2 and the GC receptor (GR), demonstrated by co-immunoprecipitation assays and co-immunofluorescence imaging. Investigation of the RUNX2/GR interaction may lead to the development of bone-sparing GC treatment modalities for the management of autoimmune and inflammatory diseases.
22
Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation
Patricia Ducy, Rui Zhang, Valérie Geoffroy et al. · Cell · 1997 · 4.3K citations · Full text
Endocrine Regulation of Energy Metabolism by the Skeleton
Na Kyung Lee, Hideaki Sowa, Eiichi Hinoi et al. · Cell · 2007 · 2.5K citations · Full text
Robert S. Weinstein, R L Jilka, A. M. Parfitt et al. · Journal of Clinical Investigation · 1998 · 1.8K citations · Full text
Medicine, Endocrinology, Aging +16